Comparison of effects of aliskiren-based combination therapy between CCB and ARB in hypertensive patients with chronic kidney disease
Phase 4
- Conditions
- Hypertension, chronic kidney disease
- Registration Number
- JPRN-UMIN000006821
- Lead Sponsor
- Department of Medical Science and Cardiorenal Medicine, Yokohama City University Graduate School of Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 100
Inclusion Criteria
Not provided
Exclusion Criteria
1) CKD stage 5 or on dialysis therapy 2) History of hypersensitivity to aliskiren, amlodipine, or valsartan. 3) Pregnant or suspicious women. 4) Treatment with itraconazole, cyclosporine. 5) Judged as inappropriate for the study
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method 1.Body weight, BMI, abdominal circumference. 2.Clinic BP 3.Home BP 4.Ambulatory BP 5.Renal function (eGFR), urinary protein and albumin excretion, urinary sodium excretion. Urinary type IV collagen and angiotensinogen. 6.Vascular function. Central BP, ABI/PWV, FMD. 7.Glucose metabolism markers. 8.Lipid metabolism markers. 9.Endocrine system. PRA, PAC, BNP. 10.Inflammatory and oxidative stress markers.
- Secondary Outcome Measures
Name Time Method